Organon Q1 revenue $1.567B (+8% ex-FX); adj. EPS $1.65; reaffirms FY guidance

Organon & Co.

2022-Q1 EPS reported $1.36 revenue$1,567,000,000

Revenue $1,567M, +4% as-reported / +8% ex-FX vs Q1 2021; Women's Health -5%, Biosimilars +22%, Established Brands +10%.
Net income from cont. ops $348M ($1.36 diluted EPS); adjusted net income $420M ($1.65 adj. diluted EPS).
Adjusted EBITDA $647M; gross margin 64.2% (adj. 66.5%); board declares $0.28 quarterly dividend.
Full year 2022 financial guidance reaffirmed; acquired rights to Marvelon/Mercilon and Xaciato license in certain markets.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.